Patents by Inventor Ge Zhang

Ge Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Controlling immune response to specific antigens
    Patent number: 6689605
    Abstract: One major problem with adenovirus gene therapy has been the T-cell mediated immune response elicited by inoculation of adenovirus, which leads to rapid clearance of the virus and loss of transgene expression. In the instant invention, the immune response to a virus is prevented by pre-treatment with adenovirus, adenoassociated virus or herpes virus infected antigen-presenting cell (APC) expressing Fas ligand with induced T-cell tolerance. Administration of AdCMVLacZ after tolerance resulted in prolonged expression of LacZ in tolerized animals compared to control treated animals. In control, but not tolerized animals, there was proliferation of CD3+ T-cell in the spleen in response to AdCMVLacZ treatment. Tolerance induction is also indicated by decreased production of interferon-&ggr; and IL-2 by peripheral T-cells isolated from treated animals after stimulation with the adenovirus infected APCs.
    Type: Grant
    Filed: January 2, 2000
    Date of Patent: February 10, 2004
    Assignee: UAB Research Foundation
    Inventors: John D. Mountz, David T. Curiel, Huang-Ge Zhang
  • Method for the augmentation of gene expression
    Patent number: 6419919
    Abstract: The present invention provides a method of increasing adenoviral gene expression in a tissue of an animal, comprising the step of administering to said animal a pharmacologically effective dose of tumor necrosis factor binding protein. Also provided is a various method of method of reducing an inflammatory response associated with adenoviral administration in a tissue of an animal, comprising the step of administering to said animal a pharmacologically effective dose of tumor necrosis factor binding protein.
    Type: Grant
    Filed: November 6, 1998
    Date of Patent: July 16, 2002
    Inventors: John D. Mountz, Huang-Ge Zhang, Tong Zhou, Carl K. Edwards, III
  • Methods of producing high titer recombinant adeno-associated virus
    Patent number: 6383794
    Abstract: The present invention discloses a method of producing large-scale recombinant adeno-associated virus stocks by infection of cells with at least one recombinant adenovirus vector(s). The vector(s) encode a therapeutic gene flanked by the terminal repeat ends of adeno-associated virus and the adeno-associated virus rep and cap genes. Transfection with two recombinant adenovirus vector(s) instead of two plasmids plus adenovirus results in the large scale, high titer production of recombinant adeno-associated virus with little to no contaminating adenovirus present.
    Type: Grant
    Filed: August 24, 1999
    Date of Patent: May 7, 2002
    Assignee: UAB Research Foundation
    Inventors: John D. Mountz, Huang-Ge Zhang
  • METHOD FOR THE AUGMENTATION OF GENE EXPRESSION
    Publication number: 20010008881
    Abstract: The present invention provides a method of increasing adenoviral gene expression in a tissue of an animal, comprising the step of administering to said animal a pharmacologically effective dose of tumor necrosis factor binding protein. Also provided is a various method of method of reducing an inflammatory response associated with adenoviral administration in a tissue of an animal, comprising the step of administering to said animal a pharmacologically effective dose of tumor necrosis factor binding protein.
    Type: Application
    Filed: November 6, 1998
    Publication date: July 19, 2001
    Inventors: JOHN D. MOUNTZ, HUANG-GE ZHANG, TONG ZHOU, CARL K. EDWARDS